Kolon Life Science Inc. (KOSDAQ:102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
61,000
+2,900 (4.99%)
Apr 28, 2026, 3:30 PM KST
117.47%
Market Cap 798.53B
Revenue (ttm) 208.98B
Net Income (ttm) 24.96B
Shares Out 13.09M
EPS (ttm) 1,824.00
PE Ratio 33.44
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,346
Average Volume 29,176
Open 58,800
Previous Close 58,100
Day's Range 58,400 - 61,900
52-Week Range 23,500 - 72,700
Beta 0.17
RSI 58.28
Earnings Date Apr 3, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Chemicals
Sector Materials
Founded 2000
Employees 425
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.